Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using an amyloid precursor protein (APP)-derived peptide in a living body-derived sample as an index, and a method for analysis thereof. A living body-derived sample derived from a test subject is measured, and at least one ratio selected from the group consisting of APP669-711/APP672-713 (A?1-42); APP672-709 (A?1-38)/APP672-713 (A?1-42); APP674-711 (A?3-40)/APP672-713 (A?1-42); APP672-710 (A?1-39)/APP672-713 (A?1-42); APP672-711 (A?1-40)/APP672-713 (A?1-42); and APP672-711 (OxA?1-40)/APP672-713 (A?1-42) is calculated, and when each of the ratios of the test subject is higher than each of standard levels which are ratios of a person having normal cognitive function NC? who is negative for cerebral A? accumulation, an accumulation amount of cerebral A? of the test subject is determined as larger than an accumulation amount of cerebral A? of the person having normal cognitive function NC?.
Type:
Grant
Filed:
May 19, 2015
Date of Patent:
January 25, 2022
Assignees:
Shimadzu Corporation, National Center for Geriatrics and Gerontology
Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.
Type:
Grant
Filed:
June 21, 2019
Date of Patent:
January 11, 2022
Assignees:
University of Florida Research Foundation, Inc., Banyan Biomarkers, Inc.
Inventors:
Kevin Ka-Wang Wang, Monika Oli, Ming-Cheng Liu
Abstract: The present disclosure provides monoclonal antibodies that bind ?-Synuclein. In certain aspects, the antibodies preferentially bind to ?-Synuclein fibrils over ?-Synuclein monomer. In other aspects, the invention comprises a method of treating ?-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting ?-Synuclein fibrils using any of the antibodies of the invention.
Type:
Grant
Filed:
May 1, 2018
Date of Patent:
January 11, 2022
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
Kelvin C. Luk, Virginia M. Y. Lee, John Q. Trojanowski, Kurt R. Brunden, Dustin Covell
Abstract: The present invention concerns peptides and nucleic acids encoding the peptides, and their use for modulating large conductance Ca2+ activated K+ (BK) channel activity in cells; for treating conditions such as presbycusis (age-related hearing loss), audiogenic seizures, alcohol addiction, cancer, and neurodegenerative disease; and for delivering a cargo moiety to the brain of a subject through the blood-brain barrier.
Type:
Grant
Filed:
December 17, 2018
Date of Patent:
January 4, 2022
Assignees:
UNIVERSITY OF SOUTH FLORIDA, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Provided are agents that specifically bind a ligand of ciliary neurotrophic factor receptor (CNTFR). In certain aspects, an agent of the present disclosure is a soluble CNTFR polypeptide. The soluble CNTFR polypeptide may have an altered (e.g., reduced) binding affinity for one or more ligand-CNTFR complex subunits, an altered (e.g., increased) binding affinity for one or more CNTFR ligands, or any combination thereof. Compositions that include the agents of the present disclosure are also provided, as are methods of using the agents (e.g., for treating a cell proliferative disorder) and methods of identifying an individual as having a cell proliferative disorder associated with CNTFR signaling.
Type:
Grant
Filed:
December 6, 2017
Date of Patent:
December 28, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Jun Woo Kim, Jennifer R. Cochran, Eric Alejandro Sweet
Abstract: The present invention provides a method of producing more mature telencephalon or a progenitor tissue thereof, in vitro, from mammalian pluripotent stem cells, comprising obtaining a telencephalon marker-positive aggregate by culturing an aggregate of pluripotent stem cells in suspension in the presence of a Wnt signal inhibitor and a TGF? signal inhibitor, and further culturing the telencephalon marker-positive aggregate in suspension under a high oxygen partial pressure condition. In one embodiment, the suspension culture under a high oxygen partial pressure condition is performed in the presence of a Wnt signal enhancer and a bone morphogenetic factor signal transduction pathway activating substance.
Type:
Grant
Filed:
November 21, 2014
Date of Patent:
December 14, 2021
Assignees:
RIKEN, Sumitomo Chemical Company, Limited
Abstract: Provided are ciliary neurotrophic factor receptor (CNTFR) ligands. In certain aspects, a CNTFR ligand of the present disclosure exhibits increased affinity for CNTFR relative to the corresponding wild-type CNTFR ligand. In certain aspects, a CNTFR ligand of the present disclosure results in reduced binding affinity of glycoprotein 130 (gp130), leukemia inhibitory factor receptor (LIFR), or both, for a complex including the CNTFR ligand and CNTFR, relative to the binding affinity for a complex including the corresponding wild-type CNTFR ligand and CNTFR. In certain aspects, a CNTFR ligand of the present disclosure has both of the aforementioned properties. Also provided are pharmaceutical compositions including the CNTFR ligands, as well as methods of using the CNTFR ligands.
Type:
Grant
Filed:
December 6, 2017
Date of Patent:
November 23, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Jun Woo Kim, Jennifer R. Cochran, Eric Alejandro Sweet
Abstract: Described herein are methods, systems and compositions for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease. Also described are methods, systems and compositions to distinguish between Alzheimer's disease and Parkinson's disease. In various embodiments levels of PACAP and/or SIRT3 are analyzed for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease.
Abstract: The invention provides methods for the treatment of neonatal hypoxia and associated white matter disease or injury, particularly in infant, including neonatal, animals, particularly Periventricular Leukomalacia (PVL) comprising administering one or more CNS reactive antibody, particularly selected from IgM12, IgM22, IgM42 and IgM46. Compositions for use in treatment of white matter disease or injury in infants, particularly PVL are provided. The invention provides methods for alleviation of neuromotor or neurodevelopmental deficits associated with neonatal hypoxia and associated with white matter injury, including PVL, in an infant.
Type:
Grant
Filed:
November 6, 2015
Date of Patent:
November 23, 2021
Assignee:
Mayo Foundation For Medical Education and Research
Inventors:
Jens O. Watzlawik, Arthur E. Warrington, Moses Rodriguez, William A. Carey
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Grant
Filed:
June 11, 2016
Date of Patent:
November 16, 2021
Assignee:
ALECTOR LLC
Inventors:
Arnon Rosenthal, Kate Monroe, Francesca Avogadri-Connors
Abstract: The present invention provides detection reagents and method for determining risk of traumatic brain injury (TBI), assessment of the amount of neuronal damage, and/or susceptibility to neurodegenerative disease in a subject.
Type:
Grant
Filed:
August 21, 2018
Date of Patent:
November 16, 2021
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Abstract: Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, com-prising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecut-ive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a dis-ease or condition associated with neuronal or synaptic loss according to the disclosed regimens.
Abstract: The invention concerns a method for detecting indicators for determining diseases (disease indicators), in which aggregates of misfolded proteins play a role, and a method for selective quantitation and/or characterization of these disease indicators.
Type:
Grant
Filed:
June 25, 2014
Date of Patent:
November 16, 2021
Assignee:
FORSCHUNGSZENTRUM JUELICH GMBH
Inventors:
Dieter Willbold, Susanne Aileen Funke, Eva Birkmann, Kateryna Kravchenko, Oliver Bannach, Carsten Korth, Verian Bader, Steffen Huebinger
Abstract: Disclosed herein, inter alia, are FOXM1 modulators and methods for modulating the activity of androgen receptors in neuronal cells to treat various diseases, such as spinal-bulbar muscular atrophy, amyotrophic lateral sclerosis, and Alzheimer's disease.
Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (A?) protein. Such antibodies may be used for the modulation of A? activity and/or aggregation or amyloidosis, to study the effects of the A? protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with A? activity, aggregation, and/or amyloidosis.
Type:
Grant
Filed:
November 8, 2019
Date of Patent:
November 2, 2021
Assignee:
rPeptide LLC
Inventors:
Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
Abstract: The present disclosure provides monoclonal antibodies that bind ?-Synuclein. In certain aspects, the antibodies preferentially bind to ?-Synuclein fibrils over ?-Synuclein monomer. In other aspects, the invention comprises a method of treating ?-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting ?-Synuclein fibrils using any of the antibodies of the invention.
Type:
Grant
Filed:
August 22, 2018
Date of Patent:
October 26, 2021
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
Kelvin C. Luk, Virginia M. Y. Lee, John Q. Trojanowski, Kurt R. Brunden, Dustin Covell
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Grant
Filed:
June 11, 2016
Date of Patent:
October 5, 2021
Assignee:
ALECTOR LLC
Inventors:
Kate Monroe, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee, William Monteith, Herve Rhinn, Arnon Rosenthal
Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
Type:
Grant
Filed:
December 2, 2019
Date of Patent:
September 21, 2021
Assignees:
F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventors:
Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
Abstract: The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.
Type:
Grant
Filed:
December 25, 2017
Date of Patent:
September 14, 2021
Assignees:
KYOWA HAKKO KIRIN CO., LTD., KAGOSHIMA UNIVERSITY
Inventors:
Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Yuji Ito